IP Library Patent Application 11256289
Patent Application
App. No. 11/256,289

Enhanced cell preservative solution and methods for using same

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/256,289
Abstract

The present invention relates to an aqueous alcohol buffer solution for substantially ambient, in vitro preservation of mammalian cells for a selected duration.

Claims (41)

1 . A method of preserving cells in a solution, said method comprising the steps of;

collecting cells from a patient; and

suspending said cells in a cell preservative solution, said solution comprising;

about twenty to thirty percent alcohol;

an anti-clumping agent in an amount sufficient to prevent the cells from clumping in said solution; and

a buffering agent which maintains said solution, with the cells, at a pH of about seven;

wherein said solution maintains the structural integrity of cells at ambient temperature in vitro while increasing the solubility of hemoglobin.

2 . The solution of claim 1 wherein said alcohol is selected from the group consisting of ethanol, isopropanol, and methanol.

3 . The solution of claim 1 wherein said alcohol is methanol.

4 . The solution of claim 1 wherein said anti-clumping agent is a chelating agent selected from the group consisting of ethylenediamine tetraacetic acid and salts thereof.

5 . The solution of claim 1 wherein said anti-clumping agent is ethylenediamine tetraacetic acid.

6 . The solution of claim 1 wherein said alcohol constitutes about 24 percent of said solution.

7 . The solution of claim 1 wherein said buffering agent is selected from the group consisting of phosphate buffered saline, Tris buffer, sodium acetate, ethylenediamine tetraacetic acid, ethylenediamine tetraacetic acid salts, citric aid and citric acid salts.

8 . The solution of claim 1 , wherein said aqueous solution contains an antibacterial agent.

9 . The solution of claim 1 wherein said buffering agent is selected from the group consisting of magnesium acetate, calcium acetate, potassium chloride, and sodium chloride.

10 . The solution of claim 1 further comprising a mucolytic agent.

11 . A method of preserving cells in a solution, said method comprising the steps of;

collecting cells from a patient; and

suspending said cells in a cell preservative solution, said solution comprising;

about 24% methanol or ethanol by volume;

about 0.07% ProClin 300 antibacterial agent;

about 3 mM EDTA,

about 200 parts per million cholic acid,

about 0.1% sodium chloride,

about 5 mM potassium chloride,

about 1 mM calcium acetate, and

about 6 mM magnesium acetate at a final pH of 7.0.

wherein said solution maintains the structural integrity of cells at ambient temperature in vitro while increasing the solubility of hemoglobin.

12 . A method of preserving cells to render them useful for subsequent immunological, genetic, or cytological analysis, wherein the method comprises the steps of:

collecting cells from a patient;

suspending said cells in a cell preservative solution, said solution comprising; about twenty to thirty percent alcohol; an anti-clumping agent in an amount sufficient to prevent the cells from clumping in said solution; and a buffering agent which maintains said solution, with the cells, at a pH of about seven; and

removing a portion of said preserved cells for immunological, genetic, or cytological analysis.

13 . The solution of claim 12 wherein said alcohol is selected from the group consisting of ethanol, isopropanol, and methanol.

14 . The solution of claim 12 wherein said alcohol is methanol.

15 . The solution of claim 12 wherein said anti-clumping agent is a chelating agent selected from the group consisting of ethylenediamine tetraacetic acid and salts thereof.

16 . The solution of claim 12 wherein said anti-clumping agent is ethylenediamine tetraacetic acid.

17 . The solution of claim 12 wherein said alcohol constitutes about 24 percent of said solution.

18 . The solution of claim 12 wherein said buffering agent is selected from the group consisting of phosphate buffered saline, Tris buffer, sodium acetate, ethylenediamine tetraacetic acid, ethylenediamine tetraacetic acid salts, citric aid and citric acid salts.

19 . The solution of claim 12 , wherein said aqueous solution contains an antibacterial agent

20 . The solution of claim 12 wherein said buffering agent is selected from the group consisting of magnesium acetate, calcium acetate, potassium chloride, and sodium chloride.

21 . The solution of claim 12 further comprising a mucolytic agent.

Assignments (3)
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
PATENT SECURITY AGREEMENT Recorded Jul 29, 2008
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0879 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2007
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P.
Reel/Frame 020018/0529 →